Editorial: The microbiome and gastric mucosal protection in aspirin users—Authors' reply

Research output: Contribution to journal › Editorial › Research › peer-review

Standard

Editorial : The microbiome and gastric mucosal protection in aspirin users—Authors' reply. / Løn, Nina; Engel, Sara; Damholt, Anders; Wellejus, Anja; Knop, Filip K.

In: Alimentary Pharmacology and Therapeutics, Vol. 59, No. 4, 2024, p. 577-578.

Research output: Contribution to journal › Editorial › Research › peer-review

Harvard

Løn, N, Engel, S, Damholt, A, Wellejus, A & Knop, FK 2024, 'Editorial: The microbiome and gastric mucosal protection in aspirin users—Authors' reply', Alimentary Pharmacology and Therapeutics, vol. 59, no. 4, pp. 577-578. https://doi.org/10.1111/apt.17826

APA

Løn, N., Engel, S., Damholt, A., Wellejus, A., & Knop, F. K. (2024). Editorial: The microbiome and gastric mucosal protection in aspirin users—Authors' reply. Alimentary Pharmacology and Therapeutics, 59(4), 577-578. https://doi.org/10.1111/apt.17826

Vancouver

Løn N, Engel S, Damholt A, Wellejus A, Knop FK. Editorial: The microbiome and gastric mucosal protection in aspirin users—Authors' reply. Alimentary Pharmacology and Therapeutics. 2024;59(4):577-578. https://doi.org/10.1111/apt.17826

Author

Løn, Nina ; Engel, Sara ; Damholt, Anders ; Wellejus, Anja ; Knop, Filip K. / Editorial : The microbiome and gastric mucosal protection in aspirin users—Authors' reply. In: Alimentary Pharmacology and Therapeutics. 2024 ; Vol. 59, No. 4. pp. 577-578.

Bibtex

@article{58c2e9b81e3a4a1391d4f1d6baf9cf15,
title = "Editorial: The microbiome and gastric mucosal protection in aspirin users—Authors' reply",
abstract = "We thank Dr. Taha for his editorial on our article.1, 2 As discussed by Dr. Taha in a recent article for the British Society of Gastroenterology, the risk of NSAID-induced gastrointestinal damage should be addressed during long-term NSAID treatment, and we compliment Dr. Taha for emphasising the potential of a safe dietary supplement such as the probiotic strain Bifidobacterium breve Bif195 (DSM 33360), for aspirin users.3 We agree that alternative treatment strategies that may enable safe continuous NSAID treatment are warranted.",
author = "Nina L{\o}n and Sara Engel and Anders Damholt and Anja Wellejus and Knop, {Filip K.}",
note = "Funding Information: The author's declaration of personal and funding interests are unchanged from those in the original article.2",
year = "2024",
doi = "10.1111/apt.17826",
language = "English",
volume = "59",
pages = "577--578",
journal = "Alimentary Pharmacology and Therapeutics, Supplement",
issn = "0953-0673",
publisher = "Wiley-Blackwell",
number = "4",

}

RIS

TY - JOUR

T1 - Editorial

T2 - The microbiome and gastric mucosal protection in aspirin users—Authors' reply

AU - Løn, Nina

AU - Engel, Sara

AU - Damholt, Anders

AU - Wellejus, Anja

AU - Knop, Filip K.

N1 - Funding Information: The author's declaration of personal and funding interests are unchanged from those in the original article.2

PY - 2024

Y1 - 2024

N2 - We thank Dr. Taha for his editorial on our article.1, 2 As discussed by Dr. Taha in a recent article for the British Society of Gastroenterology, the risk of NSAID-induced gastrointestinal damage should be addressed during long-term NSAID treatment, and we compliment Dr. Taha for emphasising the potential of a safe dietary supplement such as the probiotic strain Bifidobacterium breve Bif195 (DSM 33360), for aspirin users.3 We agree that alternative treatment strategies that may enable safe continuous NSAID treatment are warranted.

AB - We thank Dr. Taha for his editorial on our article.1, 2 As discussed by Dr. Taha in a recent article for the British Society of Gastroenterology, the risk of NSAID-induced gastrointestinal damage should be addressed during long-term NSAID treatment, and we compliment Dr. Taha for emphasising the potential of a safe dietary supplement such as the probiotic strain Bifidobacterium breve Bif195 (DSM 33360), for aspirin users.3 We agree that alternative treatment strategies that may enable safe continuous NSAID treatment are warranted.

U2 - 10.1111/apt.17826

DO - 10.1111/apt.17826

M3 - Editorial

C2 - 38247147

AN - SCOPUS:85182630736

VL - 59

SP - 577

EP - 578

JO - Alimentary Pharmacology and Therapeutics, Supplement

JF - Alimentary Pharmacology and Therapeutics, Supplement

SN - 0953-0673

IS - 4

ER -

ID: 381054169